FDA Expert Witness Services

Leverage The Most Trusted FDA Experts in the World

When litigation hinges on FDA compliance and regulatory interpretation, credibility and clarity are everything. ProPharma's expert witness consulting services deliver unparalleled insight, strategic support, and courtroom-ready testimony from the largest team of former FDA and senior industry professionals in the world. Whether you're involved in a business dispute, product liability case, patent issue, or pursuing damages in a regulatory dispute, we provide expert guidance rooted in real-world FDA experience and scientific rigor.

Comprehensive FDA Expertise Across Product Areas

We support legal teams and life sciences clients in a wide range of matters involving FDA-regulated products, including:

  • FDA Enforcement Actions: 483 observations, warning letters, consent decrees, import detentions, and recalls
  • Product Development & Approval Pathways: NDAs, ANDAs, 510(k)s, PMAs, De Novo submissions, and combination product strategies
  • Pharmaceutical, Biotech & Device Litigation: Adulteration, misbranding, product liability, and regulatory negligence claims
  • Advertising & Promotional Compliance: OPDP compliance, off-label promotion, fair balance, and substantiation disputes
  • Clinical Trials & GCP Compliance: Site inspections, data integrity, informed consent violations, protocol deviations
  • Manufacturing & Quality Systems: cGMP/QSR deficiencies, supplier quality, CAPAs, MDRs, and risk management gaps

Our team of FDA Expert Witness Consultants brings an insider’s perspective to every case—identifying gaps, explaining regulatory expectations, and anticipating FDA interpretations that can sway outcomes.

Why Choose ProPharma's Team of FDA Expert Witness Consultants?

Our expert team sets the global standard for FDA-related litigation support. We offer:

Unmatched Regulatory Expertise

Our roster is comprised of more former FDA employees than any other consulting firm—including former reviewers, inspectors, compliance officers, and division directors who understand FDA expectations from the inside out. Our bench also consists of many senior industry executives, with an impressive breadth and depth of scientific and regulatory expertise.

Scientific and Strategic Depth

In addition to regulatory backgrounds, our experts are PhD/MD scientists, clinical trialists, engineers, and manufacturing specialists with deep domain knowledge across the product lifecycle.

Credible, Court Tested Authority

We are the most trusted FDA expert witnesses in the world, with extensive experience supporting clients in federal and state courts, arbitration panels, and regulatory hearings.

Clarity That Persuades

Our consultants translate complex regulatory and scientific concepts into clear, defensible testimony that resonates with judges, juries, and legal counsel alike.

Strategic Support at Every Stage of Litigation

Whether you're building your case or preparing for trial, we serve as a strategic partner throughout the legal process:

  • Early Case Assessment: We help legal teams evaluate regulatory strengths and weaknesses and refine case strategy
  • Expert Reports & Declarations: Our experts craft detailed, objective reports that withstand scrutiny and communicate clearly
  • Deposition & Trial Testimony: Our seasoned experts are skilled at delivering confident, credible testimony that holds up under cross-examination
  • Rebuttal & Opposing Expert Analysis: We review and critique the opinions and assumptions of opposing FDA experts to help you anticipate challenges and build counterpoints

From technical assessments to high-stakes testimony, ProPharma’s expert witness consultants deliver the insight and authority your case needs.

biotech-startup-team-being-shown-a-presentation

Who We Serve

Casually worker business professionals collaborating at a conference table

Our FDA expert witness services are trusted by top-tier clients around the world, including:

  • Law Firms representing pharmaceutical, medical device, biotechnology, and diagnostics companies in civil, criminal, and regulatory matters
  • Life Sciences Companies facing litigation, government investigations, product recalls, or shareholder actions
  • Insurance Providers & Risk Managers seeking defensible analysis of regulatory compliance and product safety claims
  • Litigation Support Firms in need of high-caliber expert evaluation, documentation review, and testimony

When regulatory credibility is on the line, leading firms rely on our unparalleled FDA knowledge and litigation support capabilities.

Partner with the World's Leading FDA Experts

With the largest team of former FDA professionals and globally recognized scientific and regulatory expertise, we are the trusted authority for FDA expert witness support. Our consultants have shaped policy, led inspections, reviewed product submissions, and now help clients succeed in high-stakes litigation.

ProPharma: The World's Leading Regulatory Consultancy

Contact us today to discuss your case and learn how our experts can strengthen your legal strategy with insight that only firsthand FDA experience can provide.

News & Insights

Understanding For-Cause Audits: A GMP Case Study

May 11, 2026

Understanding For-Cause Audits: A GMP Case Study

Explore the critical role of for-cause audits in GMP environments, uncovering how minor discrepancies can reveal systemic risks and enhance quality oversight.qua

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strategy

May 5, 2026

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strat...

Preparing for an IND submission? Discover 12 critical questions sponsors should answer to reduce FDA risk, avoid delays, and strengthen submission readiness.

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity Expectations

April 30, 2026

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity ...

Recent cyberattacks on MedTech leaders highlight growing regulatory and patient safety risks. Explore key lessons and how FDA cybersecurity guidance is shaping compliance and resilience.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Whitepapers IND Readiness Checklist: Assess Your FDA Submission Risk

May 4, 2026

IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting

A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

Understanding For-Cause Audits: A GMP Case Study

May 11, 2026

Understanding For-Cause Audits: A GMP Case Study

Explore the critical role of for-cause audits in GMP environments, uncovering how minor discrepancies can reveal systemic risks and enhance quality oversight.qua

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strategy

May 5, 2026

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strat...

Preparing for an IND submission? Discover 12 critical questions sponsors should answer to reduce FDA risk, avoid delays, and strengthen submission readiness.

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity Expectations

April 30, 2026

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity ...

Recent cyberattacks on MedTech leaders highlight growing regulatory and patient safety risks. Explore key lessons and how FDA cybersecurity guidance is shaping compliance and resilience.

Previous Post Arrow Next Post Arrow
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Whitepapers IND Readiness Checklist: Assess Your FDA Submission Risk

May 4, 2026

IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting

A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow